Recent Updates
Recently added Catalysts
OCS Neutral Sentiment

SECURITIES AND EXCHANGE COMMISSION

Key Takeaway: On November 29, 2024, Oculis Holding AG submitted a report to the Securities and Exchange Commission concerning transactions by managerial personnel in compliance with EU Market Abuse Regulation. This notification complies with the filing requirements under the Securities Exchange Act of 1934. The report includes managerial transactions as detailed in Exhibit 99.1. Sylvia Cheung, Chief Financial Officer, signed the report.
Price reaction · baseline $16.16 (2024-11-27 close) · hit after-hours · clean, no other OCS news in the window
day 0 close · peak
-0.7%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
3.8%
average across 4 past catalysts
Lead asset
Privosegtor
Phase 3 · Optic Neuritis

Full Press Release Details

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2024
(Commission File No. 001-41636)
(Translation of registrant's name into English)
(Address of registrant's principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 29, 2024, Oculis Holding AG (the Registrant ) provided notification and public disclosure of transactions by persons discharging managerial responsibilities ( PDMR ) and persons closely associated with them in accordance with the requirements of the EU Market Abuse Regulation ( MAR ), which are attached hereto as Exhibit 99.1.
Exhibit Description
99.1 PDMR notifications pursuant to MAR, dated November 29, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
OCULIS HOLDING AG
Date: November 29, 2024 By: /s/ Sylvia Cheung
Sylvia Cheung Chief Financial Officer

Frequently Asked Questions

What does the report pertain to?

The report relates to transactions by persons discharging managerial responsibilities at Oculis Holding AG.

When was the report filed?

The report was filed on November 29, 2024.

Who signed the report on behalf of Oculis Holding AG?

The report was signed by Sylvia Cheung, the Chief Financial Officer.

What regulation does the report comply with?

The report complies with the EU Market Abuse Regulation (MAR).

What type of report is this document?

This document is a report of a foreign issuer under Rule 13a-16.

Last updated: Nov 29, 2024